Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice

Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice

EULAR has released 12 evidence-based recommendations for the use of imaging in the diagnosis and monitoring of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.

First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA

First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA

The FDA has expanded the approval of mepolizumab for treating eosinophilic granulomatosis with polyangiitis, which causes vasculitis.

Azathioprine With Glucocorticoids in Nonsevere Systemic Necrotizing Vasculitides

Azathioprine With Glucocorticoids in Nonsevere Systemic Necrotizing Vasculitides

Adding azathioprine to glucocorticoids has no significant benefit for patients with nonsevere systemic necrotizing vasculitides.

Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Biomarkers Identified

Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Biomarkers Identified

Several circulating biomarkers for antineutrophil cytoplasmic antibody-associated vasculitis disease activity and organ involvement were identified using targeted serum proteomics.

Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis

Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis

Central airway disease and a nodular pattern of pulmonary involvement occurred significantly more often in PR3-ANCA-positive patients than in MPO-ANCA-positive patients.

Increased Cardiovascular Risk Factor Prevalence in Takayasu's Arteritis

Increased Cardiovascular Risk Factor Prevalence in Takayasu's Arteritis

The risk for cardiovascular events was higher in patients with Takayasu's arteritis.

FDA Approves First Drug to Specifically Treat Giant Cell Arteritis

FDA Approves First Drug to Specifically Treat Giant Cell Arteritis

Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.

FDA Gives Tocilizumab Priority Review Status for Giant Cell Arteritis

FDA Gives Tocilizumab Priority Review Status for Giant Cell Arteritis

FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.

Increased VTE Risk in GCA With and Without Glucocorticoids

Increased VTE Risk in GCA With and Without Glucocorticoids

Patients experienced an elevated risk of venous thromboembolism both immediately before and immediately after giant cell arteritis diagnosis.

Rituximab Decreases Malignancy Risk in ANCA-Associated Vasculitis

Rituximab Decreases Malignancy Risk in ANCA-Associated Vasculitis

A retrospective analysis has shown that patients with ANCA-associated vasculitis treated with rituximab have a much lower risk of developing subsequent malignancies when compared with those treated with cyclophosphamide.

Sign Up for Free e-newsletters